Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration by Maximova, Natalia et al.
1Maximova N, et al. J Immunother Cancer 2020;8:e000388. doi:10.1136/jitc-2019-000388
Open access 
Rapid recovery of postnivolumab 
vemurafenib- induced Drug Rash with 
Eosinophilia and Systemic Symptoms 
(DRESS) syndrome after tocilizumab 
and infliximab administration
Natalia Maximova   ,1 Alessandra Maestro,2 Davide Zanon,2 Annalisa Marcuzzi3
To cite: Maximova N, 
Maestro A, Zanon D, et al.  Rapid 
recovery of postnivolumab 
vemurafenib- induced Drug Rash 
with Eosinophilia and Systemic 
Symptoms (DRESS) syndrome 
after tocilizumab and infliximab 
administration. Journal for 
ImmunoTherapy of Cancer 
2020;8:e000388. doi:10.1136/
jitc-2019-000388
Accepted 09 January 2020
1Bone Marrow Transplant Unit, 
Institute for Maternal and Child 
Health—IRCCS Burlo Garofolo, 
Trieste, Italy
2Pharmacy and Clinical 
Pharmacology Unit, Institute for 
Maternal and Child Health—
IRCCS Burlo Garofolo, Trieste, 
Italy
3Department of Chemical and 
Pharmaceutical Sciences, 
University of Ferrera, Ferrera, 
Italy
Correspondence to
Dr Natalia Maximova;  
 natalia. maximova@ burlo. 
trieste. it
Case report
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Background Immune checkpoint inhibitors such as 
nivolumab and targeted BRAF inhibitors have dramatically 
altered the treatment outcomes of metastatic melanoma 
over the past few years. Skin toxicity is the most common 
adverse event (AE) related to the commonly used BRAF 
inhibitor vemurafenib, affecting more than 90% of patients. 
Vemurafenib- related severe AEs with early onset are 
reported in patients who were previously treated with 
anti- programmed cell death-1 (anti PD-1) antibodies. A 
prolonged administration of systemic steroids is the first- 
line treatment of severe or life- threatening AEs. We report 
the case of a woman suffering from vemurafenib- related 
severe, rapidly worsening Drug Rash with Eosinophilia and 
Systemic Symptoms (DRESS) syndrome, resolved in a few 
hours after single- dose administration of a combination of 
TNF-α antagonist infliximab with interleukin (IL)-6 receptor 
antagonist tocilizumab.
Case presentation A 41- year- old woman treated with 
single- agent nivolumab presented with a melanoma 
progression. Biopsy samples were revised, revealing 
a BRAF V600E mutation. The patient was started on 
vemurafenib and cobimetinib treatment only 10 days 
after the last administration of nivolumab. On the third 
day of anti- BRAF therapy, profound lymphopenia was 
detected, and maculopapular eruption appeared afterward. 
Subsequently, the clinical conditions deteriorated further, 
and the woman was admitted on an emergency basis with 
high fever, respiratory and cardiocirculatory failure, diffuse 
rash, generalized edema, and lymphadenopathy. Diagnosis 
of DRESS syndrome with overexpressed capillary leakage 
was made. A single dose of tocilizumab was administered 
with an improvement of cardiocirculatory and renal 
function in a few hours. Because of worsening of liver 
function, skin lesions and mucositis, a single dose of 
infliximab was prescribed, and dramatic improvement was 
noted over the next 24 hours. Dabrafenib and trametinib 
were initiated, and coinciding with washout of infliximab 
from the patient’s blood, the drug toxicity recurred.
Conclusion Anti- IL-6 and anti- TNF-α target treatment 
of very severe AEs may afford an immediate resolution 
of potentially life- threatening symptoms and reduce the 
duration and the costs of hospitalization. Maintenance of 
therapeutic infliximab blood concentrations permits an 
early switch to dabrafenib after vemurafenib- related AEs.
BACkgRound
Targeted therapy currently represents a 
promising therapy for malignancies, such as 
metastatic melanoma with the BRAF V600 
mutation, that are refractory to conventional 
chemotherapies. Vemurafenib was licensed 
for the treatment of nonresectable metastatic 
melanoma by the Food and Drug Administra-
tion Agency in the USA in August 2011 and by 
the European Medicines Agency in Europe in 
February 2012.1 Unfortunately, the duration 
of BRAF inhibitor- induced responses proved 
too short in all treated patients because of 
the development of resistance. The primary 
resistance mechanism to BRAF inhibition is 
reactivation of the MAPK pathway.2 The clin-
ical evidence of the benefit, however, led to 
approval in 2015 of the use of combinations 
vemurafenib plus cobimetinib as well as 
dabrafenib plus trametinib.3
Skin toxicity is the most common adverse 
event (AE) related to vemurafenib, affecting 
more than 90% of patients.4 5 Grade 3 skin 
toxicity is observed in a variable percentage 
from 15% to 40% of treated patients. In 
contrast, grade 4 skin toxicity is uncommon 
in clinical studies, with an incidence that does 
not exceed 1%.6 However, the rate of severe 
AEs occurring in patients treated with vemu-
rafenib in real- life conditions is reported to 
be significantly higher.7
Vemurafenib- related severe AEs with 
early onset are reported in patients who 
were previously treated with anti- PD-1 (anti- 
programmed cell death-1) antibodies, espe-
cially in the preceding 4 weeks.8 9 According 
to preliminary evidence, the combination of 
BRAF/MEK- inhibitors with anti- PD-1 anti-
bodies results in a significantly higher toxicity 
profile compared with current treatment 
protocols, with more than half of patients 
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experiencing a grade 3–5 AE and 40% discontinuing at 
least one of the drugs in phase II of their ongoing clinical 
trial KEYNOTE-022.10
A prolonged administration of systemic steroids, after 
interruption of a culprit drug, is the first- line treatment 
of severe or life- threatening AEs. Several case reports 
describe the second- line successful treatment with intra-
venous immunoglobulin, cyclosporine, cyclophospha-
mide, mycophenolate mofetil, and plasmapheresis.11 The 
duration of clinical and biological abnormality is 35 days 
on average in the severe AEs with systemic involvement.7
In this manuscript, we report the case of a woman 
suffering from vemurafenib- related severe, rapidly 
worsening Drug Rash with Eosinophilia and Systemic 
Symptoms (DRESS) syndrome. Disease progression was 
stopped in a few hours after a combination of TNF-α 
antagonist infliximab with interleukin (IL)-6 receptor 
antagonist tocilizumab single- dose administration.
CASe pReSenTATion
A 41- year- old woman was diagnosed with AJCC stage IB 
melanoma on her back (Breslow index, 4.65 mm) in June 
2016 in Ukraine. At the time, she was treated only with 
radical resection of primary tumor. Disease progression 
with primary lesion recurrence ensued over the next 
2 years. Breast, lung, spleen, liver, subcutaneous fat, and 
axillary lymph node involvements were documented when 
a CT scan was performed. She was treated with primary 
lesion debulking and axillary lymph node curettage. 
Subsequently, after her arrival in Italy, she began anti- PD-1 
(nivolumab) and tolerated four cycles of therapy without 
side effects but developed new splenic, hepatic, and bone 
metastases. Biopsy samples were revised, and molecular 
testing revealed a BRAF V600E mutation. A combination 
of anti- BRAF and anti- MEK therapy was proposed. The 
patient was started on vemurafenib 960 mg two times a 
day and cobimetinib 60 mg once a day.
On the third day (D+3) of anti- BRAF therapy, profound 
lymphopenia (210/mm3) was detected. The following 
day (D+4) maculopapular eruption predominating 
on the photo- exposed areas appeared. Treatment was 
continued, and a topical corticosteroid was prescribed. 
The rash worsened over the next days (figure 1), high 
fever and fatigue also manifested, and 3 days later (D+7) 
the patient was admitted on an emergency basis with life- 
threatening conditions.
At admission she presented with a highly painful 
erythematous rash covering more than 80% of the body 
surface, hemorrhagic crusting on the lips (figure 2), oral, 
and nasal mucositis, generalized edema more promi-
nent in the face, inguinal lymphadenopathy, fever of 
39.7°C with chills, hypotension, oliguria, and shortness of 
breath with desaturation (SaO2 84% in room air). The 
examination demonstrated decreased breath sounds 
and dullness to percussion over the lower two- thirds of 
both hemithoraxes. Lung ultrasound was performed, 
and bilateral pleural effusion was documented. Labora-
tory testing demonstrated leukocytosis (16,700/mm3) 
with 98.7% of neutrophils, C reactive protein 145.7 mg/L 
(n.r.<5 mg/L), procalcitonin 4.11 µg/L (n.r.<0.5 µg/L), 
lactate dehydrogenase 717 U/L (n.r. <250 U/L), creatine 
phosphokinase 824 U/L (n.r. 25–170 U/L), serum creat-
inine 1.53 mg/dL (baseline value 0.70 mg/dL), alanine 
aminotransferase (ALT) 188 U/L and aspartate amino-
transferase (AST) 193 U/L (n.r. <35 U/L), cholinesterase 
activity 3004 U/L (n.r. 3930–10,800 U/L), serum albumin 
2.32 g/dL (n.r. 3.50–5.20 g/dL), complement C3 63 mg/
dL (n.r. 90–180 mg/dL), and complement C4 6 mg/dL 
(n.r. 10–40 mg/dL). Blood cultures, FilmArray Respira-
tory Panel (RP2 plus) and Pneumonia Panel (Pneumo 
plus), real- time PCR for cytomegalovirus (CMV), Epstein- 
Barr virus (EBV), Adenovirus, herpes simplex virus 
(HSV), human herpes virus (HHV)-6, HHV-7, HHV-8, 
Parvovirus B19 were all negative.
Vemurafenib and cobimetinib were discontinued at 
once. The patient was started on a powerful intravenous 
saline solution with albumin, prednisone 2 mg/kg/day, 
broad- spectrum antibiotics, continuous furosemide infu-
sion, and antihistamine medication. She also underwent 
noninvasive ventilation used high flow oxygen therapy Figure 1 Highly painful confluent erythematous macules.
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with an AIRVO device because of increasing (up to 10 L/
min) oxygen requirement.
The next day the patient’s clinical condition worsened 
even more: low urine output was evident in weight gain, 
the edema worsened leading to anasarca, renal function 
deteriorated, and hypotension requiring vasopressor 
support ensued. DRESS syndrome with overexpressed 
capillary leakage symptomatology was suspected. Using 
the RegiSCAR scoring system, our case registered a score 
of 7 points and was therefore classified as definite DRESS 
syndrome.12 Despite the mucosal involvement, a diagnosis 
of Stevens- Johnson syndrome was discounted because of 
the severity of systemic symptoms. In an attempt to inter-
rupt capillary leakage of fluid in the interstitial space, the 
patient was treated with a single, 8 mg/kg, dose of tocili-
zumab (D+9), an IL-6 receptor antibody. Progression of 
body weight gain and edema was halted, and blood pres-
sure and renal function improved in a few hours. Diuretic 
and vasopressor supports were discontinued, oxygen 
requirement was drastically reduced, and noninvasive 
ventilation was replaced with the conventional nasal 
cannula. Oxygen support was finally suspended 2 days 
later (D+11).
Together with the restoration of hemodynamic and 
respiratory functions, the liver function tests (LFTs) 
worsened (ALT 450 U/L, AST 339 U/L), and eosino-
philia (930 cells/mm3) and thrombocytopenia appeared. 
Oddly, the immunoglobulin M went up to 693 mg/
dL (n.r. 40–230 mg/dL). The cutaneous involvement 
did not have decisive improvement. Mucosal lesions 
also remained unchanged, making any enteral intake 
impossible. Three days after tocilizumab administration 
(D+12), the patient received a single dose (5 mg/kg) of 
infliximab, the TNF-α-blocking agent. Dramatic improve-
ment of skin lesions and mucositis was noted over the next 
24 hours (D+13), and the patient was discharged the next 
day. The hospitalization lasted only 7 days. At follow- up 
1 week after discharge (D+20), the physical examina-
tion was unremarkable, no cutaneous or mucosal lesions 
were noted, the LFTs were normal, and the patient had 
resumed regular feeding. She began a rapid prednisone 
tapering (D+25; D+32).
Because of the benefit of BRAF inhibitors on her meta-
static disease, relatively young age and good general 
condition, dabrafenib and trametinib were initiated 
1 month after discharge without signs of drug toxicity 
(D+53; D+67). Two weeks after the start of dabrafenib, at 
the same time as washout of infliximab from the patient’s 
blood, high fever without other symptoms recurred 
(D+71). Fortunately, she could continue the dabrafenib 
treatment after the addition of cortisone (0.5 mg/kg) 
without further complications.
We evaluated the concentration of plasma cytokines, 
using inflammatory multiplexed panel, at every signif-
icant phase of this case. Of 27 proinflammatory and 
regulatory cytokines and chemokines evaluated, the 
levels of 24 molecules greatly exceeded those normal for 
age, while IL-12 and granulocyte- macrophage colony- 
stimulating factor (GM- CSF) concentrations were below 
the normal range, and only IL-1β values remained 
around the normal values. The marked increase in the 
concentration of cytokines was found only during the 
active phase of the drug- related inflammatory process 
for IL- 1ra, IL-6, IL-10, interferon (IFN)-γ, interferon-γ 
inducible protein-10 (IP-10)/CXCL10, monocyte chemo-
attractant protein-1 (MCP-1)/CCL2, and macrophage 
inflammatory protein-1α (MIP-1α)/CCL3 (figure 3). 
Consistently high values, even during remission, have 
been documented for IL-5, macrophage inflammatory 
protein-1β (MIP- 1b)/CCL4, regulated on activation, 
Figure 3 Cytokine profile at every point of time in the case report. Columns of serum level (pg/mL) of IL- 1ra, IL-2, IL-6, 
IFN-γ, IP-10/CXCL10, MCP-1/CCL2, MIP-1α/CCL3, TNF-α at all times analyzed (D+7, D+9, D+11, D+12, D+13, D+20, D+25, 
D+32, D+53, D+67, D+71). The physiological cytokine levels in healthy subjects (HS; n=35) (≥18 years old) are represented by 
the dashed line. Data analyses were performed with one- way analysis of variance (ANOVA) test followed by the Bonferroni’s 
correction D+3 vs D+13 and D+20 vs D+71; *p<0.05, **p<0.01, ***p<0.001, NS: nonsignificant. ANOVA, analysis of variance; IP-
10, inducible protein-10; MCP-10, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory protein-1α.
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normal T cell expressed and secreted (RANTES)/CCL5, 
Eotaxin/CCL11, fibroblast growth factor (FGF), granulo-
cyte colony- stimulating factor (GCSF), and vascular endo-
thelial growth factor. Remarkably, even TNF-α values, 
although significantly decreased, remained permanently 
high despite infliximab treatment.
All data of cytokines and chemokines concentration 
are shown in online supplementary figures S1–S3. Inflix-
imab therapeutic drug monitoring and the more signif-
icant plasma cytokine level tendencies are illustrated in 
figure 4.
diSCuSSion
DRESS syndrome, also known as drug- induced hypersen-
sitivity syndrome, is a rare, potentially life- threatening 
rash with eosinophilia and systemic symptoms. Reported 
DRESS- related mortality rates are approximately 10% 
or higher, depending on the degree and type of organ 
involvement, even with proper medical management.11
Usually, the onset of DRESS syndrome is 2 months 
following culprit drug initiation. Our patient developed 
the first signs of skin toxicity on the fourth day from the 
start of vemurafenib- cobimetinib therapy. Some recent 
publications have shown that previous treatment with 
anti- PD1 drugs is associated with the early onset and the 
severity of vemurafenib- induced skin disorders, including 
hypersensitivity syndrome.13–15 Our patient started anti- 
BRAF therapy only 10 days after the last administration 
of nivolumab, without a sufficiently long washout period. 
Though the nivolumab treatment was well- tolerated, it may 
have triggered the immune system, leading to severe drug 
toxicity. The reduction in immune checkpoint inhibition 
caused by nivolumab may have predisposed the patient 
to a skin hypersensitivity reaction caused by vemurafenib. 
The overlapping of the two phenomena can explain this 
predisposition. First, vemurafenib caused marked tumor 
infiltration of CD8+ cytotoxic T lymphocytes. Furthermore, 
the presence of functional host cytotoxic T cells may have 
played an essential role in effecting responses to BRAF 
inhibitor therapy.16 Second, the immune checkpoint inhib-
itors strongly provoked activation of CD8+ cytotoxic T cells, 
which are also the key cellular mediators in drug- induced 
skin toxicity.17 High levels of IP-10/CXCL10 and MCP-1/
CCL2 plasma concentration, which were documented in 
our patient only at the onset, that is, in the active phase of 
DRESS, confirm this process. IP-10/CXCL10 with MCP-1/
CCL2 plays a significant role in CD8+ T cell recruitment 
and in leucocyte homing to inflamed tissues, exacerbating 
inflammation and causing substantial tissue damage.18
More than 90% of patients treated with vemurafenib 
experience AEs; 26% of them develop grade 3–4 skin 
toxicity.7 19 We documented a severe lymphopenia in our 
patient as early as 2 days after initiation of anti- BRAF treat-
ment. The previous report of Imafuku et al suggested that 
lymphopenia is a useful marker of vemurafenib- induced 
AEs and may be used as an indicator for reduction of vemu-
rafenib dosage to prevent the appearance of severe side 
effects.20 The authors demonstrated a positive correlation 
between the grade of lymphopenia and the severity of AEs. 
We found the increase of IL- 1ra, in addition to profound 
lymphopenia, at the early onset of anti- BRAF- related AE. We 
have documented the high concentrations of IL- 1ra both at 
the onset of DRESS and the manifestation of dabrafenib- 
related fever, before the significant increase of the other 
cytokines and chemokines analyzed.
Development of severe skin adverse reactions such as 
DRESS, Steven- Johnson syndrome or toxic epidermal 
necrolysis, besides indicating immediate discontinuation 
of vemurafenib, permanently contraindicates its use.7 
For those who do not respond to immune checkpoint 
blockade therapy, it is equivalent to a death sentence 
because of the extremely severe course of metastatic 
malignant melanoma after vemurafenib withdrawal.21 
The successful use of dabrafenib in case of vemurafenib- 
induced severe AEs have been reported.7 22–24 For a safe 
switch to dabrafenib, complete remission of vemurafenib- 
related toxicity symptoms is required. One month is the 
mean time to a full recovery with no sequelae, which is 
reported in the literature.13 The disease can undergo a 
rapid progression in 1 month. High level of immunoglob-
ulin M, the potent inhibitor of the excessive inflammatory 
response25 found in our patient’s blood, confirmed the 
increased activity of the inflammatory process. Targeted 
treatment with drugs that are selective inhibitors of the 
production of cytokines involved in severe drug- related 
toxicity, such as tocilizumab, can significantly modify the 
clinical outcomes and allow the rapid resumption of anti- 
melanoma therapy. Mori et al recently demonstrated that 
elevated levels of IL-6 and TNF- a might predict a poor 
outcome in patients with cancer with severe cutaneous 
adverse reactions.26 Extremely high levels of IL-6 and 
Figure 4 Graph of the trends of cytokine plasma and 
infliximab serum concentration during the vemurafenib- 
related DRESS treatment course and at the time of 
dabrafenib reintroduction. D 0 (day 0) coincides with the 
beginning of vemurafenib treatment. Note the drop of plasma 
concentration of all cytokines/chemokines displayed after 
treatment with monoclonal antibodies. Their levels remain low 
until infliximab is a washout, when the cytokines start to rise, 
particularly the IL- 1ra.
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TNF-α at the DRESS onset (70 and 20 times greater than 
the normal range, respectively) provide the rationale for 
treatment with targeted monoclonal antibodies.
However, we need to consider another important matter. 
Though combination BRAF and MEK inhibition extend 
the duration of response, most tumors develop adaptive 
resistance within a relatively short interval. In the first- line 
setting, the proportion of patients free of disease progres-
sion at 6 months is 72.3%, survival at 12 months is 76.9% and 
at 24 months, 53.5%.27 Recently reported in the literature 
is a significant increase in overall survival within the first 3 
months of patients who experienced severe vemurafenib- 
related skin toxicity.7 The explanation for the findings is 
that immunomodulatory therapies and inflammation due 
to vemurafenib trigger the patient’s antitumor immunity, 
inducing the systemic release of cytokines and activation 
of natural killer (NK) and cytotoxic T lymphocytes. In our 
case, we documented an elevated plasma concentration 
of IL-2 at each evaluation, which proved particularly high 
during acute DRESS phase. IL-2 has a pleiotropic role in 
the maintenance of the balance between the promotion 
and inhibition of the immune response. This equilibrium 
allowed to obtain promising results from the clinical ther-
apeutic application of IL-2 in the trial in patients with 
metastatic melanoma.28–30 Despite the development of 
new therapeutic approaches, high- dose IL-2 remains an 
important option for patients with melanoma and has an 
improved therapeutic window in the current era.31 Three 
chemokine proteins that were reproducibly detected in 
abundance in the T- cell- rich melanoma were MCP-1/
CCL2, MIP-1β/CCL4, and RANTES/CCL5, while most 
melanoma cell lines showed expression predominantly 
of IL-8/CXCL8 only.32 As a result, the lack of CD8+ T cell 
recruitment chemokines can explain the worst outcomes 
of antimelanoma treatment. The most relevant chemok-
ines for effector CD8+ T cell migration could be considered 
MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4, RANTES/
CCL5, CXCL9, and IP-10/CXCL10. Transmural migration 
assays document that each of these chemokines was suffi-
cient to recruit CD8+ effector T cells primed from healthy 
donors in vitro.25 Our data document that at the onset of 
DRESS, the values of all of these chemokines is markedly 
elevated (CXCL9 was not analyzed). While the values  of 
IP-10/CXCL10, MCP-1/CCL2 and MIP-1α/CCL3 return 
within the normal range after monoclonal antibodies are 
used, the levels of MIP-1β/CCL4 and RANTES/CCL5 
remain persistently high, even when the DRESS symptoms 
disappear.
ConCluSion
First- line therapy options for metastatic melanoma treat-
ment currently include BRAF inhibitors or immune 
checkpoint inhibitors. The better sequence for these 
treatments has not yet been defined. A switch to BRAF 
inhibitors after immunotherapy failure must be carried 
out under close medical control with prompt identifi-
cation of patients who develop profound lymphopenia. 
If profound lymphopenia is detected, the IL- 1ra blood 
concentration determination could be useful in predicting 
the severity of drug- related toxicity and in taking deci-
sions about treatment interruption. Anti- IL-6 and anti- 
TNF-α target treatment of very severe AEs may yield 
an immediate resolution of potentially life- threatening 
symptoms and reduce the duration and the costs of 
hospitalization. Maintenance of therapeutic infliximab 
blood concentrations for 9 weeks permits an early intro-
duction of dabrafenib after vemurafenib- related AEs. Use 
of infliximab during extreme systemic inflammation such 
as DRESS does not reset the TNF-α levels but only lowers 
them. Thus, the risk of infections due to its use does not 
increase. The “protective” blood concentration of inflix-
imab boosts antitumor immunity, maintaining the high 
levels of proinflammatory cytokines, without AEs.
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